2129 N Congress Ave, Riviera Beach, FL 33404 [email protected] 561.847.2302

World Sickle Cell Day

In support of World Sickle Cell Day, the Sickle Cell Disease Coalition is raising awareness of SCD in Africa and the rest of the world in an effort to improve health outcomes for people with the disease from infancy… Read More

Sancilio Pharmaceuticals Company Announces Altemia™ Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Pediatric Patients with Sickle Cell Disease (SCD)

This follows the Orphan Drug Designation for Altemia™ granted by the U.S. Food and Drug Administration (FDA) in 2015 RIVIERA BEACH, Fla. – April 3rd, 2018 – Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced that the European Commission has… Read More

Sancilio Pharmaceuticals Company, Inc. Announces the Successful Completion of a Randomized, Double Blind, and Placebo Controlled Phase of a Clinical Trial in Pediatric Patients with Sickle Cell Disease using AltemiaTM

RIVIERA BEACH, Fla. – October 03, 2017 (BUSINESS WIRE)–Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the successful completion of a randomized, double blinded, placebo controlled clinical trial in pediatric sickle cell patients aged 5 – 17 years old…. Read More

Sancilio Pharmaceuticals Company, Inc (SPCI) Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for Altemia(TM) a Treatment of Sickle Cell Disease (SCD) in Children

RIVIERA BEACH, Fla. – October 03, 2017 (BUSINESS WIRE)–Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the successful completion of a randomized, double blinded, placebo controlled clinical trial in pediatric sickle cell patients aged 5 – 17 years old…. Read More